Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Carasent ASA

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
3.10.
2022
In order to align the interest of the new CEO (Daniel Øhman, starting November
1, 2022) and the new Chairman of the Board (Petri Niemi, assuming he is elected
at the extraordinary shareholder meeting October 19, 2022) with the
shareholders' interest in building shareholder value, the Board in Carasent ASA
has approved a stock option program.
Tiedotteet
3.10.
2022
The subscription term for the stock options issued on November, 2019 starts on
October 1, and ends on November 30, 2022.

The total numbers of issued options are 2 million with a strike price of NOK
14.47 per share.

The Board of Carasent has decided to use the right to settle the options in
cash. The cash amount will be settled based on average volume-weighted share
quoted for the 20 trading days period in advance of November 30, 2022.
Tiedotteet
28.9.
2022
Attched is the Calling Notice for an Extraordinary General Meeting for October
19, 2022, as well at the proposal from the Company's Nomination Committee.

The Shareholder Meeting will be arrange as physical meeting with possibility for
digital participation. If not present in person, the attached voting form must
be used.

Please use the attached Voting Form for attendance and voting.
Tiedotteet
15.9.
2022
September 15, 2022, Oslo

After having acted as Chairman of the Board of Directors in Carasent for
approximately 15 years, Johan Lindqvist announces that he will step down from
the position. Lindqvist will continue as Chairman until the next extraordinary
general meeting of Carasent, where a successor will be appointed. The company's
Nomination Committee has initiated the search process for a new Chairman.
Tiedotteet
1.8.
2022
Carasent has entered into a partnership agreement with the Norwegian company
Confrere 4 AS ("Confrere"), a market leader in Norway within video software for
healthcare practices.

Confrere was established in Norway in 2018 and has rapidly become the leading
provider of video solutions for physicians in Norway. Confrere has a highly
attractive customer base primarily in the Norwegian market, focusing on primary
care clinics, therapists and hospitals.
Tiedotteet
28.7.
2022

Redeye updates its estimates following Carasent’s Q2’22 report, which was a tad weaker than anticipated. Both the organic growth and margins came in below estimates. On the bright side, the customer intake was very strong, and Carasent also signed its first Webdoc NO customer.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

Tiedotteet
15.7.
2022
Attached please find Carasent ASA Q2 and H1, 2022 Financial Result Presentation.

For further information, please contact
CFO Svein Martin Bjørnstad, tel: 47 979 69 493
Tiedotteet
15.7.
2022
Attached please find Carasent ASA Financial Report for Q2 and H1, 2022.

For further information, please contact
CFO Svein Martin Bjørnstad, tel: 47 979 69 493
Tiedotteet
12.7.
2022
Carasent ASA will present its Q2 and H1, 2022 Financial Results as a webcast on
July 15, at 8:00 a.m.

Please use the following link for the webcast:
https://channel.royalcast.com/landingpage/hegnarmedia/20220715_1/

Welcome.
Tiedotteet
16.6.
2022
June 16, 2022

The board of directors of Carasent ASA ("Carasent" or "the Company") has today
appointed Daniel Öhman as the Company's new Chief Executive Officer (CEO). He
will succeed Dennis Höjer who has been CEO since December 2020. Öhman will start
no later than 2 January 2023.

Daniel Öhman is at present CEO of GHP Speciality Care, a role he has held since
2013. During Öhman's leadership, GHP Specialty Care's valuation increased from
370 MSEK to 2 450 MSEK, turnover doubled, and EBITDA increased from 50 MSEK to
200 MSEK.

Carasent ASA